History of aerosol therapy: Liquid nebulization to MDIs to DPIs

Respiratory Care

Volumn 50, Issue 9, 2005, Pages 1139-1149

  Anderson, Paula J ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Aerosol; Asthma; Bronchodilator; Drug delivery; Dry powder inhaler; Inhaler; Lung disease; Metered dose inhaler; Nebulizer; Scintigraphy

Indexed keywords

ADRENALIN; ANTIINFECTIVE AGENT; CHLOROFLUOROCARBON; IMMUNOSUPPRESSIVE AGENT; ISOPRENALINE; STRAMONIUM; ANTIASTHMATIC AGENT;

AEROSOL; ASTHMA; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE REPLACEMENT THERAPY; HISTORY OF MEDICINE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG DEPOSIT; LUNG DISEASE; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; PARTICLE SIZE; POWDER INHALER; SCINTIGRAPHY; SYSTEMIC THERAPY; THEORETICAL MODEL; ARTICLE; CERAMICS; EQUIPMENT DESIGN; HISTORY; INSTRUMENTATION; PHARMACOKINETICS; POWDER; SCINTISCANNING;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; CERAMICS; CHLOROFLUOROCARBONS; EQUIPMENT DESIGN; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; LUNG DISEASES; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHARMACOKINETICS; POWDERS; RADIONUCLIDE IMAGING;

EID: 33644629923     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975; 51(Suppl 7):13-20.
2. Maimonides M. Treatise on Asthma (The Medical Writings of Moses Maimonides) Muntner S, editor. Philadelphia: Lippincott; 1963.
3. Scudder JM. Eclectic manual no. 2 on the use of medicated inhalations in the treament of diseases of the respiratory organs. Cincinnati: John M Scudder's Sons; 1895:21.
4. Mark Sanders. Mudge inhaler. http://www.inhalatorium.com/ page57.html. Accessed June 20, 2005.
5. Scudder JM. Eclectic manual no. 2 on the use of medicated inhalations in the treament of diseases of the respiratory organs. Cincinnati: John M Scudder's Sons; 1895:22.
6. Dessanges J. A history of nebulization. J Aerosol Med 2001;14(1): 65-71.
7. Mark Sanders. Sales-Girons pulverisateur. http://www.inhalatorium. com/page148.html. Accessed June 20, 2005.
8. Aiache J. Aerosol therapy in France. J Aerosol Med 1990;3(2):85-120.
9. Scudder JM. Eclectic manual no. 2 on the use of medicated inhalations in the treament of diseases of the respiratory organs. Cincinnati: John M Scudder's Sons; 1895:23-24.
10. Grossman J. The evolution of inhaler technology. J Asthma 1994; 31(1):55-64.
11. Snell N. The carbolic smoke ball. Int J Pharm Med 2001;15:195-196.
12. Rau JL. Inhaled adrenergic bronchodilators: historical development and clinical application. Resp Care 2000;45(7):854-863.
13. Aranson R, Rau JL. The evolution of beta-agonists. Respir Care Clin N Am 1999;5(4):479-519.
14. Walker IC. Bronchial asthma. In: Christian HA editor. The Oxford Medicine. New York: Oxford University Press; 1932;217-243.
15. Mark Sanders. The Pneumostat. http://www.inhalatorium.com/ page131.html. Accessed June 20, 2005.
16. Mark Sanders. The London Inhalatorium. http://www.inhalatorium. com/page134.html. Accessed June 20, 2005.
17. Freedman T. Medihaler therapy for bronchial asthma: a new type of aerosol therapy. Postgrad Med 1956;20(6):667-673.
18. American Thoracic Society statement on intermittent positive-pressure breathing (IPPB). Respir Care 1979;24(8):698-699.
19. Braun SR, Smith FR, McCarthy TM, Minsloff M. Evaluating the changing role of respiratory therapy services at two hospitals. JAMA 1981;245(20):2033-2037.
20. Conference on the scientific basis of respiratory therapy. Final reports: summaries and recommendations. Am Rev Respir Dis 1974; 110(6 Pt 2):7-9.
21. Findeisen W. Uber das absetzen kleiner, in der luft suspendierter teilchen in der menschlichen lunge bei der atmung. Arch Ges Physiol 1935;236:367-379. (article in German)
22. Swift D. Use of mathematical aerosol deposition models in predicting the distribution of inhaled therapeutic aerosols. In: Hickey AJ, editor. Inhalation Aerosols: Physical and biological basis for therapy (Lung Biology in Health and Disease series, volume 94). New York: Marcel Dekker; 1996;51-81.
23. Landahl HD. On the removal of air-borne droplets by the human respiratory tract: I. The lung. Bull Math Biophys 1950;12:43-56.
24. Bates DV, Fish BR, Hatch TF, Mercer TT, Morrow PE. Deposition and retention models for internal dosimetry of the human respiratory tract. Task group on lung dynamics. Health Phys 1966;12(2):173-208.
25. Hinds WC. The lung and the environment. Semin Respir Med 1980; 1(3):197-210.
26. Weibel ER. Morphometry of the human lung. Berlin: Springer-Verlag; 1963.
27. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002;19(3):239-245.
28. Martonen TB, Musante CJ, Segal RA, Schroeter JD, Hwang D, Dolovich MA, et al. Lung models: strengths and limitations. Respir Care 2000;45(6):712-736.
29. Landahl HD, Tracewell TN, Lassen WH. On the retention of airborne particulates in the human lung. Arch Ind Hyp Occup Med 1951;3(4):359-366.
30. Altshuler B, Yarmus L, Palmes ED, Nelson N. Aerosol deposition in the human respiratory tract. Arch Industl Health 1957;15(4):293-303.
31. Heyder J, Gebhart G, Heigwer G, Roth C, Stahlhofen W. Experimental studies of the total deposition of aerosol particles in the human respiratory tract. Aerosol Sci 1973;4:191-208.
32. Morrow PE. Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. Am Rev Respir Dis 1974;110(6 Pt 2):88-99.
33. Hinds WC. Aerosol technology. New York: John Wiley & Sons; 1982:211-232.
34. Clark AR, Gonda I, Newhouse MT. Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols. J Aerosol Med 1998; 11(Suppl 1):S1-S7.
35. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Metered-dose inhaler (MDI) and dry powder inhaler (DPI) drug products (draft). October, 1998. http://www.fda. gov/cder/guidance/2180dft.htm. Accessed June 20, 2005.
36. Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Snell NJC, Ganderton D, editors. Resp Med 1999;93(2):123-133.
37. Anger HO. Scintillation camera. Rev Sci Instr 1958;29:27-33.
38. Newman SP, Pitcairn GR, Hirst PH, Rankin L. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003;55(7):851-867.
39. Newman SP. Deposition and effects of inhalation aerosols. Lund: Rahns i Lund Tryckeri AB; 1983.
40. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001;6(7):367-375.
41. Borgström L, Newman S, Weisz A, Moren F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992;81(8):753-755.
42. Leach CL. Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol 1995;22(4):328-334.
43. Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998;92 Suppl A:9-15.